Alnylam Pharmaceuticals announced its preliminary Q4 and FY23 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. Preliminary global net product revenues for ONPATTRO and AMVUTTRA for the fourth quarter were approximately $79M and $175M, respectively, representing 10% total TTR quarterly growth compared to Q3 2023, and for the FY23 were approximately $355M and $558M, respectively, representing 40% total TTR annual growth compared to FY22. As of year-end 2023, over 4,060 patients worldwide were receiving commercial ONPATTRO or AMVUTTRA. Preliminary global net product revenues for GIVLAARI and OXLUMO for the fourth quarter were approximately $59M and $33M, respectively, representing 11% total Ultra-Rare quarterly growth compared to Q3 2023, and for FY23 were approximately $219M and $110M, respectively, representing 35% total Ultra-Rare annual growth compared to FY22. As of year-end 2023, over 650 patients worldwide were receiving commercial GIVLAARI and over 430 patients were receiving commercial OXLUMO. Further, at December 31, 2023, Alnylam had preliminary cash, cash equivalents, and marketable securities of approximately $2.4B, as compared to $2.2B at December 31, 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Alnylam price target raised to $220 from $216 at Bernstein
- William Blair sees ATTR-PN market as large enough for two players
- Citi says approval ‘likely’ for Ionis’ eplontersen ATTR-PN NDA
- Alnylam price target raised by $7 at Piper Sandler, here’s why